Loading…
← CockpitCompetitor Analysis › DSGN Design Therapeutics, Inc.Open in the cockpit ↗

Design Therapeutics, Inc.DSGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 19
Mkt cap
$606M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$3.59M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.7%
Hurdle
n/a
no reverse DCF
Next earnings
117 days
15 Mar 2027
Close · USD$9.47
1D-3.8%
1W-12.1%
1M-14.7%
3M-39.1%
6M-14.7%
YTD+1.0%
1Y+27.5%
ATR %6.8%
Beta1.24
52w lowhigh45.1% off high

What Design Therapeutics does

Employees: 124

Design Therapeutics at a glance

Size Design Therapeutics (DSGN) is a United States Health Care company (Biotechnology) with a market value of $606M, the 2547th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.47 on 18 Nov 2026.

Performance Over six months the shares fell 14.7%, against -25.6% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.

Short interest Short interest is 9.9% of the free float (30 Oct 2026).

Next results Next results expected around 15 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026DSGN 86Peer median 75
Six months, rebased to 100: Design Therapeutics against the median of its 20 peers (local-currency closes).

Design Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$600,000-$622,000-$596,000-$537,000-$466,000
EBITDA-$81.7M-$78.8M-$61.8M-$77.7M-$67.1M
Net income-$74.1M-$69.8M-$49.6M-$66.9M-$63.3M
Free cash flow-$59.4M-$54.6M-$43.4M-$58.8M-$52.7M
Capital expenditure$70,000$193,000$340,000$256,000$918,000
Total debt$2.51M$1.53M$2.33M$3.05M$3.69M

Quarterly statements and history in the cockpit →

Design Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-100%0%+100%+200%+300%0%+50%SRZN688639603387JANXFDMTGERN1672GNFT68819730087199667729DSGN6-month return →1-month return →
Up and to the right = strong over both horizons. Design Therapeutics is the large dot.

Design Therapeutics competitors and peer comparison

How Design Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Design Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureDSGNPeer medianRank in peer set
1-month return-14.7%-16.5%10th highest of 21
6-month return-14.7%-25.6%8th highest of 20
Distance from 52-week high-45.1%-48.2%10th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a

Questions

Which companies are Design Therapeutics's closest peers?
The cockpit's peer set: Surrozen (SRZN), Anhui Huaheng Biotechnology (688639.SS), Alebund Pharmaceuticals (Jiangsu) (9637.HK), Getein Biotech (603387.SS), Janux Therapeutics (JANX), Shenzhen Weiguang Biological Products (002880.SZ), 4D Molecular Therapeutics (FDMT), Geron (GERN).
How has Design Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -14.7% against -25.6% for the median peer; over one year +27.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.